Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-ERA: V114 for prevention of vaccine-type acute otitis media in children
2023-001146-11Phase 3
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of pneumococcal 15-valent conjugate vaccine in acute otitis media (AOM) and pneumococcal disease, sponsored by Merck & Co. Primary endpoints: Number of participants with a first episode of vaccine-type acute otitis media (VT-AOM) and Proportion of participants with serious adverse events (SAEs).
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
acute otitis media (AOM)pneumococcal disease
Beyond the preview
Go deeper on 2023-001146-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001146-11.